Chart-Typ:
Zeitraum:
| Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen |
| Arcutis Biotherapeutics, Inc.: Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology | ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeksOnce-daily ZORYVE foam 0.3% is approved... ► Artikel lesen |
| Arcutis Biotherapeutics, Inc.: Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results | Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and... ► Artikel lesen |
| Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46%... ► Artikel lesen |
| Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results | ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology... ► Artikel lesen |
| Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on October 6, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics... ► Artikel lesen |
| Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen |
| Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 | Initiated a second potentially registrational study of IMVT-1402 in Graves' disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren's disease (SjD), both in June 2025All other... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PILA PHARMA AB finden Sie auf Wallstreet Online.